Gynecology Drugs Global Market Report 2024

The gynecology drugs market size has grown strongly in recent years. It will grow from $41.56 billion in 2023 to $43.78 billion in 2024 at a compound annual growth rate (CAGR) of 5.4%. The expansion observed in the historical period can be attributed to several factors, including the introduction of drugs with novel mechanisms, increased availability of educational tools and awareness regarding menopause, a rise in the use of long-acting reversible contraceptives, shifts in lifestyles, heightened healthcare awareness and expenditure, government initiatives, and an increase in pharmaceutical research and development (R&D) expenditure.

The gynecology drugs market size is expected to see strong growth in the next few years. It will grow to $54.1 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The forecasted growth is driven by increased awareness and use of contraceptives and hormone replacement therapy (HRT), a rise in age-related gynecological cancers, higher ovarian cancer cases, prevalence of gynecological diseases, increased healthcare expenditure, and investments in understanding endometriosis mechanisms. Key trends include launching new treatments for oncology and endometriosis, developing menopausal hormone therapies, research investments in gynecology drugs, awareness efforts on contraceptive benefits, product launches for unmet needs, antibody-drug conjugates for ovarian cancers, strategic collaborations for portfolio expansion, and focus on combination therapies to address drug resistance in cancer treatments.

The anticipated increase in the number of women affected by ovarian cancer is expected to drive growth in the global gynecological drugs market. Ovarian cancer, originating in the ovaries as part of the female reproductive system, is effectively managed by gynecological drugs that offer targeted treatment options, improved survival rates, and enhanced quality of life for patients. According to estimates from Globocan, the global incidence of ovarian cancer is projected to reach 434,184 by 2040, thereby fostering the demand for gynecological drugs in the foreseeable future.

Age serves as a significant risk factor for various diseases, including diabetes, obesity, neurodegenerative disorders, and cancer. In particular, disruptions in female reproductive cycles, such as early menarche or late menopause, contribute to hormonal imbalances and increase the risk of cancer in later stages of life. Endometrial and ovarian cancers are prevalent among elderly women and contribute to substantial mortality rates. The incidence of these cancers rises with age, typically peaking around 60 to 70 years. Additionally, cervical cancer is commonly diagnosed around the age of 50, while vaginal and vulvar cancers are typically diagnosed later, around the age of 67. For instance, the American Cancer Society estimates 14,000 new cases of cervical cancer in the United States in 2022. The age-related upswing in gynecological cancers is expected to propel the market in the coming years.

There is a noteworthy trend in the pharmaceutical industry where companies are investing in the development of personalized cancer vaccines, including those for gynecological cancers. Some of these vaccines have progressed to clinical trial phases, demonstrating the industry's commitment to leveraging genetic sequencing and precision medicine for patient-specific drug therapies. Notably, Moderna reported positive results from an ongoing Phase 1 clinical study of its mRNA-4157 personalized cancer vaccine, designed for patients with both resected and unresected solid tumors. The vaccine is currently in Phase 2 clinical trials.

The introduction of gynecological drug treatments by major companies represents a positive trend in the market. Given the competitive landscape and the presence of multiple players, companies are focusing on advanced drug development to introduce new and effective treatments. For example, in September 2021, Myovant Sciences, a UK-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had accepted a supplemental New Drug Application (sNDA) for MYFEMBREE, a drug designed to manage moderate to severe pain associated with endometriosis. The FDA set a target action date of May 6, 2022, for the sNDA under the Prescription Drug User Fee Act (PDUFA).

In March 2022, Carlyle, a U.S.-based private equity firm, and PAI Partners, a France-based private equity firm, reached an agreement to acquire Theramex from CVC Capital Partners for $1.4 billion. This acquisition is intended to expand the investment portfolio of Carlyle and PAI in Theramex, focusing on organic, inorganic, and international growth initiatives. Theramex, a UK-based pharmaceutical company, specializes in women's health products related to fertility, contraception, menopause, and osteoporosis.

Major companies operating in the gynecology drugs market report are Merck & Co. Inc., AbbVie, Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Pfizer Inc., Furukawa Electric, Motherson Sumi, LS Cables & Systems, HUBER+SUHNER., Acome, Yazaki Corporation, Fujikura Ltd., Robert Bosch, HELLA GmbH & Co. KGaA, Coroplast Harness Technology Sp. z oo sp. k, EK Elektrokabel FABRYKA KABLI Karolak i synowie sp. z o.o., Coroflex Poland Sp. z o.o Sp. k., Eltrim Kable Sp. z o. o, Anixter, Allied Wire & Cable Inc., Emcocables, Navcar S.A.S, Wirex Cable SA, Sistemas de Argentina S.A, ARJ Water Technology LLC, Fajr Al Hind LLC, Haji Commercial Co LLC, Bahra Cables, Coficab Group.

North America was the largest region in the gynecology drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gynecology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gynecology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary therapeutic categories within gynecology drugs include hormonal therapy and non-hormonal therapy. Hormonal therapy involves treatments that either add, block, or remove hormones to impede the growth of cancer cells reliant on hormones for their development. Non-hormonal therapy includes the use of anti-infective and anti-inflammatory agents, lubricants, moisturizers, as well as medications such as antidepressants, gabapentin, clonidine, among others. Gynecology drugs find application in treating conditions such as gynecological cancers, menopausal disorders, polycystic ovary syndrome, contraception, and more. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The gynecology drugs market research report is one of a series of new reports that provides gynecology drugs market statistics, including gynecology drugs industry global market size, regional shares, competitors with a gynecology drugs market share, detailed gynecology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gynecology drugs industry. This gynecology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gynecology market consists of sales of belantamab, relugolix, selumitinib, and avapritinib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.